Skip to content

Research Areas

Biosfer Teslab has more than 90 publications in multiple research areas. 

Abstract  Several studies suggest that variations in the concentration of plasma glycoproteins can influence cellular changes in a large number of diseases. …

Abstract  Background Supplementation with omega-3 (n-3) fatty acid or dietary fish may protect against atherosclerosis, but the potential mechanisms are unclear. Prior …

Abstract  Background: LDL-C lowering is the main measure in cardiovascular disease prevention but a residual risk of ischemic events still remains. Alterations …

Abstract  Plasma glycoproteins are a composite biomarker of inflammation and can be detected by 1H-NMR. The aim of this study was to …

Abstract  Background and aims: The first line of therapy in children with hypercholesterolaemia is therapeutic lifestyle changes (TLSC). The efficacy of lifestyle …

Abstract Background and aim: Atherosclerosis is the underlying process in cardiovascular disease (CVD), the first cause of death in developed countries. We aimed …

Abstract  Scope: Postprandial dysmetabolism plays a major role in the pathogenesis of metabolic disorders such as obesity and the polycystic ovary syndrome …

Abstract Abnormal lipid metabolism is associated with gestational diabetes mellitus (GDM) and is observed in neonates with abnormal fetal growth. However, the …

Abstract  Background: Dyslipidemia has been associated with vascular complications of type 1 diabetes mellitus (T1DM). We examined the proton nuclear magnetic resonance …

Background & aims: Patients with functional dyspepsia are believed to have increased sensitivity of the gastrointestinal tract, and some also have functional constipation. …

ACCIÓ GRANT

BIOSFER TESLAB, SL with the support of ACTION in the frame of the Operative Program FEDER Catalonia 2014-2020 has carried out the “DEVELOPMENT And VALIDATION OF ADVANCED DIAGNOSTIC TEST Of INFLAMMATION And  INSULIN RESISTANCE FOR THE IMPROVEMENT OF  CARDIOVASCULAR RISK USING NUCLEAR MAGNETIC RESONANCE”  (RD15-1-0013).

Biosfer Teslab, along the project, has developed a system of prediction, using of advanced prediction tests, with the aim to improve the evaluation of cardiovascular risk and to identify those individuals with residual cardiovascular risk that would remain undiagnosed with classical risk factors.

In particular, the company has developed a glycoprotein test and a LMWM test - that includes, branched amino acids -, as they have been identified as inflammatory markers and involved in insulin resistance processes, respectively.

The Agency for the Competitiveness of the Company, ACTION, aiding to industrial research centers and experimental development, has granted Biosfer Teslab with an amount of 67,728.97 €.

This aid is programmed in the axis 1, "Boost research, technological development and innovation", specific objective OE 1.2.2, "Transfer and spreading of technology and cooperation between companies and universities or other research centers", line of action "Collaborative R+D projects" under the framework of the FEDER Operational Program of Catalonia 2014-2020